huSiglec15-CHO is primarily used in immunological research and therapeutic development due to its role in modulating immune responses. It serves as a target for monoclonal antibodies being developed to treat bone-related diseases such as osteoporosis and certain cancers including solid tumors. Because Siglec-15 is selectively expressed on tumor-associated macrophages and osteoclasts, this molecule is valuable in targeted therapies that aim to inhibit excessive bone resorption or suppress the immunosuppressive tumor microenvironment. Its application extends to in vitro and in vivo studies for evaluating immune checkpoint inhibition, similar to PD-1 or CTLA-4 pathways, making it a candidate for next-generation cancer immunotherapies. Additionally, it is used in diagnostic assays to detect Siglec-15 expression in tissue samples, aiding in patient stratification for clinical trials.